The Beauty Health Company (NASDAQ:SKIN – Get Free Report)’s stock price traded up 5.4% on Tuesday . The stock traded as high as $4.35 and last traded at $4.33. 143,832 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 2,901,702 shares. The stock had previously closed at $4.11.
Analyst Ratings Changes
A number of equities research analysts have commented on SKIN shares. Canaccord Genuity Group raised their price target on shares of Beauty Health from $3.00 to $4.00 and gave the stock a “hold” rating in a report on Thursday, March 14th. DA Davidson restated a “buy” rating and set a $5.00 price target on shares of Beauty Health in a research note on Friday, March 15th. Piper Sandler reaffirmed an “underweight” rating and issued a $3.00 price objective (up from $2.00) on shares of Beauty Health in a research note on Wednesday, March 13th. TD Cowen upped their target price on shares of Beauty Health from $2.50 to $4.00 and gave the stock a “market perform” rating in a report on Wednesday, March 13th. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $4.00 price target (up previously from $3.00) on shares of Beauty Health in a research note on Wednesday, March 13th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $6.50.
Beauty Health Stock Up 5.8 %
The company has a market capitalization of $536.92 million, a P/E ratio of -5.52 and a beta of 0.94. The stock has a 50 day moving average price of $3.25 and a 200 day moving average price of $3.75. The company has a debt-to-equity ratio of 12.43, a quick ratio of 5.28 and a current ratio of 6.07.
Beauty Health (NASDAQ:SKIN – Get Free Report) last released its earnings results on Tuesday, March 12th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. The firm had revenue of $96.80 million for the quarter, compared to analysts’ expectations of $87.22 million. Beauty Health had a negative net margin of 25.65% and a negative return on equity of 18.85%. The company’s quarterly revenue was down 1.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.03 earnings per share. Equities research analysts forecast that The Beauty Health Company will post -0.12 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Beauty Health
Several institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada grew its stake in Beauty Health by 22.8% in the 3rd quarter. Royal Bank of Canada now owns 7,700 shares of the company’s stock valued at $91,000 after buying an additional 1,430 shares in the last quarter. Amundi raised its stake in shares of Beauty Health by 24.1% during the 4th quarter. Amundi now owns 9,032 shares of the company’s stock valued at $92,000 after purchasing an additional 1,754 shares during the period. Swiss National Bank boosted its stake in Beauty Health by 1.1% in the 2nd quarter. Swiss National Bank now owns 187,500 shares of the company’s stock worth $1,569,000 after purchasing an additional 2,100 shares during the period. State of Wyoming grew its holdings in Beauty Health by 46.4% during the 4th quarter. State of Wyoming now owns 6,791 shares of the company’s stock valued at $62,000 after buying an additional 2,152 shares in the last quarter. Finally, D.A. Davidson & CO. increased its position in shares of Beauty Health by 2.7% during the second quarter. D.A. Davidson & CO. now owns 90,670 shares of the company’s stock valued at $759,000 after buying an additional 2,388 shares during the period. 93.26% of the stock is owned by hedge funds and other institutional investors.
Beauty Health Company Profile
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company’s flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer’s preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.